TURANDOT_3: TURANDOT, figure 3

TURANDOT_3R Documentation

TURANDOT, figure 3

Description

Kaplan-Meier digitized data from TURANDOT, figure 3 (PMID 27501767). A reported sample size of 564 for a primary endpoint of OS in breast cancer.

Usage

TURANDOT_3

Format

A data frame of 564 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (bev_capecitabine, bev_paclitaxel)

Source

Zielinski C, Láng I, Inbar M, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol 2016; 17: 1230–9.

Examples

summary(TURANDOT_3)

kmplot(TURANDOT_3)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.